HOME >> MEDICINE >> NEWS
Analysis of tamoxifen studies reveals slight increase of stroke risk

ST. PAUL, Minn. A recent analysis of tamoxifen studies completed since 1980 revealed an increased risk of stroke in women who were randomized to tamoxifen versus placebo or other therapies. Details of the analysis and the researchers' conclusions are reported in the October 12 issue of Neurology, the scientific journal of the American Academy of Neurology.

More than 250,000 U.S. women are diagnosed with breast cancer each year. Breast cancer accounts for nearly one in three cancers diagnosed in the U.S. and is the second leading cause of death for women. Fortunately, 90 percent of breast cancers are now diagnosed at localized and regional stages, for which five-year survival rates are 97 percent and 79 percent, respectively. Tamoxifen, a medication in pill form that interferes with the activity of estrogen, has been used for more than 20 years to treat patients with advanced breast cancer. It is used as adjuvant, or additional, therapy following primary treatment for early stage breast cancer. In women at high risk of developing breast cancer, tamoxifen reduces the chance of developing the disease.

In addition to its effects on breast cancer, the benefits of tamoxifen include increased bone mineral density, reduced risk of hip fractures, and lower levels of cholesterol. While tamoxifen is known to increase the risk of blood clotting in women with cancer, its relationship to stroke risk has been unclear. Because tamoxifen increases the risk of thromboembolism (a blood clot that has traveled from its site of origin to another vessel), its use could be associated with a higher risk of ischemic stroke (arterial obstruction) as compared to hemorrhagic (bleeding) stroke.

Researchers from Duke University Medical Center sought to determine the overall risk of both ischemic stroke and all strokes associated with tamoxifen. They conducted a systematic review of all clinical trials of tamoxifen published since 1980 using MEDLINE.

Nine
'"/>

Contact: Marilee Reu
mreu@aan.com
651-695-2789
American Academy of Neurology
11-Oct-2004


Page: 1 2

Related medicine news :

1. Analysis finds drug improves odds of complete stroke recovery
2. Analysis of study looks at why quitters return to smoking
3. Analysis suggests women treated for breast cancer do better with axillary node dissection
4. Retrospective Statistical Analysis Corroborates Early Results Of Randomized Breast Cancer Trials
5. New U-M Analysis Of Brain At Work
6. Meta-Analysis Of The Efficacy Of Sildenafil (ViagraTM) In The Treatment Of Severe Erectile Dysfunction
7. Digital Speech Analysis Tests Sobriety
8. Common antidepressants lower effects of tamoxifen in many women
9. Study finds women hesitant to take tamoxifen as preventive measure
10. Decision to take tamoxifen difficult for many women
11. Chemotherapy, but not tamoxifen, associated with stroke risk after breast cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Analysis tamoxifen studies reveals slight increase stroke risk

(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... Dallas, TX (PRWEB) , ... August 28, 2015 , ... ... Surgical Center is taking part with their subsidiary USPI Tenet Health. , The American ... to fight heart disease and stroke. They believe that together, a difference can be ...
(Date:8/28/2015)... Hanover, MA (PRWEB) , ... August 28, 2015 , ... ... benefitting the renowned Brain Aneurysm Foundation has added yet another accolade to its ... Chicago, Rahm Emanuel. , “With the help of the medical community and ...
(Date:8/28/2015)... ... ... Saint Petersburg, FL —Pocket Protein™, a protein beverage that ... lactose or caffeine in a convenient 2 oz. pouch that never needs refrigeration, ... , Five consumer packaged goods (CPG) products were selected by the SupplySide editorial ...
(Date:8/28/2015)... ... August 28, 2015 , ... Drugs and ... James Strawbridge, gives a new approach on solutions in his new book ":Unraveling ... employer and employees getting together for meaningful group meetings. "This would educate the ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
(Date:8/27/2015)... Aug. 27, 2015  The Academy of Managed ... Drug Administration,s (FDA,s) draft guidance and proposed rule ... biosimilars, to bear a nonproprietary name with an ... seeking a decision from the FDA on the ... care stakeholders urging the agency to use the ...
(Date:8/27/2015)... Aug. 27, 2015 DURECT Corporation (Nasdaq: ... present at three upcoming healthcare conferences.  ... will present at the Rodman & Renshaw Investment Conference ... The conference is being held at the St. Regis ... A live audio webcast of the presentation will be ...
(Date:8/27/2015)... ieCrowd™ today announced the achievement of ... the company,s supplemental oxygen delivery device, Smart Oxygen ... by ieCrowd,s subsidiary Smart Oxygen Solutions TM , ... oxygen based on level of activity.  The FDA ... Smart Oxygen device would require a series of ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
Cached News: